ArticleTherapeutics and clinical risk management2022

Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database.

Takeo Hata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.